Patient perspectives on testing for clonal hematopoiesis of indeterminate potential

Clonal hematopoiesis of indeterminate potential (CHIP), an emerging biomarker for personalized risk-directed interventions, is increased in cancer survivors. However, little is known about patient preferences for CHIP testing. We surveyed participants in a prospective cohort study of young women wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sella, Tal, Fell, Geoffrey G., Miller, Peter G., Gibson, Christopher J., Rosenberg, Shoshana M., Snow, Craig, Stover, Daniel G., Ruddy, Kathryn J., Peppercorn, Jeffrey M., Schapira, Lidia, Borges, Virginia F., Come, Steven E., Warner, Ellen, Frank, Elizabeth, Neuberg, Donna S., Ebert, Benjamin L., Partridge, Ann H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791300/
https://www.ncbi.nlm.nih.gov/pubmed/36129839
http://dx.doi.org/10.1182/bloodadvances.2022008376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791300/
https://www.ncbi.nlm.nih.gov/pubmed/36129839
http://dx.doi.org/10.1182/bloodadvances.2022008376

Ejemplares similares